AstraZeneca Canada has announced today that Health Canada has approved the use of Symbicort Turbuhaler budesonide/formoterol DPI as an anti-inflammatory reliever for the treatment of mild persistent asthma. According to the company, the expanded use was based on data from the Phase 3 SYGMA 1 and 2 trials.
AstraZeneca Canada VP, Scientific Affairs Neil Maresky commented, “Health Canada’s approval supports the use of Symbicort Turbuhaler as an anti-inflammatory reliever as-needed for patients with mild persistent asthma to treat inflammation, not just asthma symptoms. It builds on the established clinical profile of the medicine as an as-needed anti-inflammatory reliever plus maintenance in moderate-to-severe disease.”
Read the AstraZeneca Canada press release.
